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Abstract Advanced glycation end products (AGEs) may
play an important role in the pathogenesis of chronic diabetic
complications and in the natural process of biological aging.
In fact, maintained hyperglycaemia favours the formation of
AGEs at the tissue level in diabetic patients, which may
influence the triggering of different chronic pathologies of
diabetes such as retinopathy, nephropathy, neuropathy and
macro- and micro-vascular diseases. Moreover, the literature
has also demonstrated the involvement of AGEs in biolog-
ical aging, which may explain the accelerated process of
aging in diabetic patients. The practice of regular physical
activity appears to positively influence glycaemic control,
particularly in type 2 diabetes mellitus patients. This occurs
through the diminution of fasting glycaemia, with a
consequent reduction of glycation of plasmatic components
suggested by the normalisation of HbA1c plasmatic levels.
This exercise-induced positive effect is evident in the blood
of diabetic patients and may also reach the endothelium and
connective tissues of different organs, such as the kidneys
and eyes, and systems, such as the cardiovascular and
nervous systems, with a local reduction of AGEs production
and further deceleration of organ dysfunction. The aim of
this paper was to review the literature concerning this topic
to coherently describe the harmful effects of AGEs in organ
dysfunction induced by diabetes in advanced age as well as
the mechanisms behind the apparent protection given by the
practice of regular physical activity.
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Introduction
Regarding its genetic predisposition and clinical specificity,
type 2 diabetes mellitus (DM2) represents a heterogeneous
pathology, characterised by chronic hyperglycaemia induced
by deficient insulin production and/or by a resistance of
target tissues to this hormone. DM2 affects approximately
2% of the world population [2], and the prevalence of this
disease is expected to increase to ∼50% by the year 2030
[147].
Prolonged exposure to hyperglycaemia is currently
recognised as the first causal factor in the majority of
DM2-related late complications [143]. Diabetic patients
with poor glycaemic control are particularly at risk for
developing associated pathologies described in humans and
in animal models, such as cataracts [101], retinopathy,
nephropathy, neuropathy [56], micro- and macro-vascular
diseases [124], cardiomyopathy [19], and impaired tissue
healing [99]. The precise mechanism involved with regard
to the role of hyperglycaemia in the pathogenesis of late
complications in diabetes is yet to be clarified. Neverthe-
less, one advanced hypothesis consists of the glycation of
proteins, a process which has been widely observed among
DM2 patients [35]. In fact, in non-compensated diabetic
patients, the blood glucose concentrations are substantially
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augmented. Contrasting with an inadequate glucose utilisa-
tion observed in muscle and adipose tissues, cells from
other organs that do not need insulin for glucose uptake
demonstrate elevated concentrations of glucose at the
intracellular level. The high amounts of glucose inside
and outside of cells favour the occurrence of spontaneous
and non-enzymatic reactions between glucose and proteins
in both intra- and extra-cellular compartments [25]. This
non-enzymatic glycation of proteins by reducing sugars
occurs in a cascade of complex reactions, resulting in a
heterogeneous class of components usually classified as
advanced glycation end products (AGEs). These types of
reactions, initially described by Louis-Camille Maillard in
1912 [81], are strongly associated with hyperglycaemia and
tissue oxidative stress [4], and suggestions of their
implication in the pathogenesis of chronic complications
in diabetes and in aging have increased [129]. On the other
hand, the natural process of aging favours the appearance
and accumulation of AGEs and of products derived from
the process of oxidation, resulting in a vicious cycle that is
difficult to stop [74]. There is a wide consensus in the
literature that the diminution of the antioxidant capacity is
the result of biological aging [64]. However, much
evidence supports the concept that regular physical exercise
chronically augments the antioxidant capacity [102], which
may impair the formation of AGEs in diabetic patients or in
individuals in advanced age.
Additionally, the practice of regular physical activity has
a positive influence on the glycaemic control, particularly
in DM2 patients, through the diminution of fasting
glycaemia with the consequent reduction of glucose
availability for glycation reactions. Accordingly, regular
physical activity may constitute an efficient weapon against
DM2-related chronic complications potentially associated
with AGEs synthesis.
In this review, we intend to analyse the literature
regarding the endogenous and exogenous sources of AGEs,
discussing the implication of these products on the aging
process and on the late complications of diabetes. Finally, the
potential protective role of physical exercise in organ
dysfunction induced by AGEs and its underling mechanisms
will also be highlighted.
AGEs: endogenous and exogenous sources
AGEs consist of a complex and heterogeneous group of
molecules, whose formation begins with a non-enzymatic
reaction between the carbonyl group of reducing sugars
with free primary amino groups of amino acids, peptides,
and proteins, or with lipids and nucleic acids [99, 110, 144].
This type of reaction is designated by non-enzymatic
glycosylation, Maillard’s reaction or also, more recently,
glycation (Fig. 1).
Amino acids are the structural units of all proteins and
are mainly composed of a primary amino group, by a
carboxyl group, and by a lateral chain that characterises
each amino acid. The linkage between different amino acids
is carried out by the reaction between the carboxyl group of
one amino acid with the amino group of the following
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Fig. 1 Sequence of events
responsible for the formation of
advanced glycation end products
(AGEs). The reaction between
glucose molecules and protein
amino groups forms the
reversible Schiff base that
suffers an intramolecular
rearrangement, leading to a
less reversible Amadori
product. In some conditions,
these Amadori products form
AGEs through a dicarbonyl
intermediate such as 3-
deoxyglucosone. According to
Ahmed [2]
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amino acid, forming the peptide bond. The establishment of
peptide links between different amino acids will create
polypeptide chains, within which the primary amino group
of the first amino acid, the so-called terminal amino group,
is available for further reactions with reducing sugars.
Moreover, amino groups belonging to lateral chains of
some amino acids, for example lysine and arginine, despite
being less reactive than a terminal amino group, may also
react with reducing sugars. However, not all the amino
groups capable of interacting with sugars actually do so
because they can be hidden in the three-dimensional
structure of the protein, therefore not permitting access to
them [50].
Endogenous glycation reactions occur in a spontaneous
way with a small proportion of absorbed simple sugars
(glucose, fructose and galactose); the amount of resultant
compounds is dependent on the grade and duration of
glucose availability, on the body’s ability to destroy and
excrete them in the urine [95], on the average length of
protein life span and on the cellular permeability to free
sugars [50]. This type of reaction is carried out in three
distinguishable stages (Fig. 1). The initial stage occurs
through the association of a sugar with a protein, resulting
in a molecular arrangement called the Schiff base. These
bases are unstable; therefore, they eventually enter into a
process of spontaneous restructuring, with the formation of
more stable products such as ketoamine or fructosamine,
termed Amadori compounds, among which HbA1c con-
stitutes a good example [5]. The formation of Schiff bases
occurs rapidly and reaches thermodynamic equilibrium
within a few hours, while in the formation of the Amadori
products, the thermodynamic equilibrium is only achieved
over a period of a few days [2]. Amadori products have a
carbonyl group that can react with other amino groups. The
exact mechanism of this reaction is not known in detail,
although it is recognised that it involves complex intramo-
lecular rearrangements and, in some cases, the association
between several of these compounds. During this second
stage, highly reactive compounds are also formed which
have two carbonyl groups acting as reaction propagators
[8]. In the final stage, a series of slow and complex
transformations occurs involving a series of rearrange-
ments, dehydrations and condensations, which lead to the
natural formation of generally coloured (brownish yellow)
and/or fluorescent compounds, denominated AGEs. In this
phase the reactions have an irreversible character, with the
formation of crossed links at the intra- and intermolecular
levels, and they occur essentially with proteins of low
turnover, as is the case for collagen and myelin (Fig. 1)
[141, 150].
Under physiological conditions, the amount of these
compounds is determined by the concentration of reducing
sugars and by the length of protein exposition to them.
With regard to the proteins of rapid turnover, this glycation
process does not normally last beyond the initial stage,
namely with the formation of Schiff bases or Amadori
products. The main problem lies in the proteins of medium
or long life (such as collagen and elastin), which ensure the
required time for the AGEs formation and accumulation
[55, 138]. Several types of AGEs observed in human
tissues are described in Table 1.
Pentosidine consists of a cross-link between the residues
of lysine and arginine (Fig. 2), and its content is augmented
in diabetic patients [83]. Crossline, initially described in
diabetic mice liver, was observed in in vivo and in vitro
studies [94]. The imidazolium dilysine cross-links are
formed through the reaction between derivates of glyoxal
and residues of lysine [52]. The 1-alkyl-2-formyl-3,4-
glycosyl-pyrroles are formed through a reaction between
two sugars and one unique residue of lysine; their presence
is increased in chronic diabetes and they probably contrib-
ute to cardiac dysfunction through interaction with type 2
ryanodine receptor calcium-release channels [33]. The
arginine–lysine imidazole cross-links were described in
Al-Abed and Bucala [7], and it is assumed that they consist
of inter-molecular cross-links. Pyrraline is a type of AGE
Table 1 Some cross-linking and non-crossed-linking AGEs that have
been most often detected in human tissues
Cross-linking AGEs
Pentosidine
Crossline
Imidazolium dilysine cross-links
1-alkyl-2-formyl-3,4-glycosyl-pyrroles
Arginine–lysine imidazole
Non-cross-linking AGEs
Pyrraline
Nɛ-carboxymethyl-lysine
Nɛ-carboxyethyl-lysine
According to Ahmed [2]
Lysine Arginine 
Fig. 2 Chemical structure of lysine and arginine molecules
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without cross-links that has been detected in the skin, in
plasma, and in the brain of patients with Alzheimer’s
disease [121]. Nɛ-carboximethyl-lysine (CML) is one of the
types of AGEs that is most abundant in vivo and whose
concentration in collagen tends to be twice as high in
diabetic patients as in non-diabetic individuals. Strong
correlations with age are also found, being described
augmentations up to fivefold from 20 to 85 years of age
[48]. They are formed by the oxidative damage of Amadori
products and during the oxidation of the methyl group of
polyunsaturated fatty acids in the presence of a protein
[106].
From the several AGEs species described, CML [61] and
pentosidine are the best chemically characterised. The
Maillard reaction has been widely used by the food industry
due to its implication in the alteration of colour, flavour,
aroma and texture of foods [80]. However, it also affects
the nutritional properties and toxicity of foods [127].
Additionally, the synthesis of AGEs typically occurs when
the sugars are cooked with proteins and/or fats. At temper-
atures above 120°C (∼248°F), an acceleration of protein
glycation occurs, but with a longer cooking time at lower
temperatures, the formation of AGEs is also promoted.
Tobacco can also be a source of AGEs due to the presence
of reactive glycated products in its extracts, as well as in the
smoke of tobacco in proportions that rapidly react with
proteins to form AGEs [34].
A diet rich in AGEs (535 units/mg of CML and 18 nmol/mg
of methylglyoxal (MG) derivatives, during 16 weeks, where
food and water intake were recorded daily for 1 week and
biweekly thereafter) promoted a 53% increase of these
substances in the serum of mice; on the other hand, a 7.8%
decrease was registered in the low-AGE-diet-mice group
(107 units/mg of CML and 3.6 nmol/mg of MG derivatives
during the same time period) [99]. In another study carried
out on 26 non-diabetic patients with renal insufficiency, an
augmentation of CML (29%) and derivates of MG (26%)
was also revealed in the blood of the group subjected to an
AGE-rich diet, while in the group subjected to a low
ingestion of AGEs, a reduction in CML (−34%) and MG
(−35%) blood content was observed [137]. These results
suggest that a restrictive diet of AGEs could be a
reasonable way to reduce excessive overloading of this
product in living tissues.
Aging and AGEs formation
At present, the contribution of the Maillard’s reaction to the
aging process is well known. The augmentation of these
compounds is responsible for the acceleration of cellular
aging through the alteration of proteins, lipids, and nucleic
acids, through the rise in oxidative stress generated in their
formation [74] and also by the interaction with the receptors
of the advanced glycation end products (RAGEs) [140]. In
recent years, these receptors have been the targets of intense
research, and a rising rate of its production has been
observed in DM2 patients [16]. It has also been suggested
that the actual process of aging favours an increase in the
formation of AGEs, essentially in the proteins of the extra-
cellular matrix [3]; its accumulation in the tissues is
dependent on time and on the concentration of glucose
[25]. Moreover, the occurrence of protein glycation is also
associated with the physiopathology of some age-related
diseases, such as arthritis, arteriosclerosis, diabetes, and
other neurodegenerative pathologies [87].
In another way, the total amount of AGEs has been
utilised as a marker of oxidative stress that is experienced
daily by the tissues. For instance, Yu and collaborators
[150] measured the methionine sulphoxide (MetSO) con-
tent in the integumentary collagen of type 1 diabetic
patients with and without late complications and in normal
individuals. An accumulation of MetSO was observed in
the collagen with advanced age. Moreover, this product
presented significantly higher values in the diabetic subjects
especially when late complications of the disease were
present [150]. In another study correlating the AGEs tissue
content with aging and diabetes [48], a 33% increase of
fructose–lysine (FL, an initial compound of glycated
products) was observed in the collagen fibres with
increased age in non-diabetic individuals, as well as
augmentations of 500% in magnitude in CML and in
pentosidine, from 20 to 85 years of age. In the same study,
diabetic patients evidenced a three-times-greater FL content
in the collagen fibres than non-diabetic individuals, which
also showed a strong correlation with the levels of glycated
haemoglobin. The authors concluded that these chemical
alterations in the collagen fibres showed a close association
with age, and that glycation reactions were accelerated in
diabetes patients. These results support the concept that
diabetes is a disease characterised by the acceleration of the
degenerative chemical mechanisms associated with biolog-
ical aging; namely, the disease affects tissue proteins with
long life span by the formation of AGEs and by enhanced
oxidative stress. The highest AGEs concentrations resulted
from both enhanced endogenous synthesis and diet, and can
also be directly implicated in the oxidative stress and
damage induced on the beta cells of the pancreatic
Langerhans islets in diabetic patients [100].
Peripheral resistance to insulin can be the most important
factor in triggering DM2, just as it is associated with an
increased risk for developing cardiovascular diseases [107].
Many of the molecular mechanisms behind insulin resis-
tance are yet to be determined; however, it is known that
they are strongly influenced by age and obesity and, apart
from other factors, are dependent on the quantity/quality of
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glucose transporting proteins GLUT4 [10, 30, 118] and of
intracellular insulin receptor substrate-1 (IRS-1) [30].
Several studies associated the formation of the AGEs with
the manifestation of peripheral resistance to insulin in
adipose tissue [136] and in skeletal muscle [85]. Enhanced
cellular oxidative stress is one of the mechanisms suggested
to explain insulin resistance, which may be the result of the
AGEs binding to RAGEs; the RAGEs stimulation appears
to interfere at various levels of the insulin signalling
pathway, and it inhibits the translocation of the GLUT4 to
the plasma membrane, with a consequent reduction of
glucose uptake [111]. Apart from the influences of age, this
mechanism also appears to be present in insulin resistance
associated with obesity [136] because a reduction in the
glucose transport mediated by insulin was recently observed
in the adipocytes of older and obese mice [30].
Oxidative stress, generally accepted as a main condi-
tioning factor for the aging process, appears to reduce the
pool of GLUT4 available in cells and the GLUT4 signalling
mechanism mediated by insulin, thus harming the cellular
glucose uptake capacity [89]. Moreover, MG appears to
bind directly to IRS-1 inside the muscle fibres, with the
direct consequence of an impairment of insulin-induced
IRS-1 tyrosine phosphorylation [108]. These data suggest a
direct influence of MG in the induction of insulin
resistance, in a way independent of oxidative stress [108].
AGEs and chronic diabetic complications
Much has been postulated in the literature over the
implication of the Maillard reaction in the aging process
or in the development of late diabetic complications [50].
Vascular diseases Vascular diseases, particularly cardiac
coronary disease, are the principal cause of premature death
in diabetic patients. Long-term studies comparing intensive
and conventional metabolic control in type 1 [56] and type
2 [135] diabetes mellitus has demonstrated a reduction in
the incidence and prevalence of cardiovascular events in
well-controlled patients. These data suggest a possible role
of hyperglycaemia in the pathology of macro-vascular
diseases in diabetes, namely through their influence in the
formation of AGEs. These products have already been
identified in atherosclerotic plaques, suggesting a possible
role of AGEs in the development of cardiovascular diseases
in diabetic patients [92]. This assumption is reinforced by
the enhanced plasmatic concentrations of AGEs found in
DM2 patients with cardiac coronary disease [62]. An
association between an increased fluorescence of integu-
mentary collagen and arterial rigidity and elevated systolic
and diastolic blood pressures has also been reported in
diabetic patients [88]. The diminution of arterial and
arteriolar elasticity has been associated with AGEs deposits
[120], and it could contribute to the development of
systemic hypertension and abnormal shear stress, predis-
posing the endothelial cells to become damaged and to
precocious arteriosclerosis [144]. Additionally, it has been
demonstrated in experimental diabetic models that amino-
guanidine inhibits the formation of this type of crosslink in
collagen fibres within the arterial walls, which reinforces the
importance of AGEs in this process [27].
The interaction of AGEs with their cellular surface
receptors (RAGEs) has been suggested to have causal
implications in the pathogenesis of diabetic vascular compli-
cations, stimulating the expression of cellular adhesive
molecules in the endothelial cells through the formation of
reactive oxygen species (ROS) [15]. During the stimulation
of RAGE, an increase in the activation of MAP kinases and
of nuclear factor-kappaB (NF-κB) has been observed, as
well as the expression of adhesion molecules in vascular
cells—the so-called vascular cell adhesion molecule-1
(VCAM-1) [51]. With respect to the cellular surface, the
endothelium is stimulated by various mediators, such as
endotoxins, TNFα, and AGEs, thus promoting an augmen-
tation in the adhesion of mononuclear proinflammatory cells,
at least partly under the influence of the VCAM-1. However,
some data [144] suggest that the action of the VCAM-1 is
not only limited to cellular adhesion events, but also induces
the activation of NADPH endothelial oxidase; this process is
essential for the migration of lymphocytes through the
stimulated cells. These observations should lead to the
assumption that the activation of RAGEs on the cell surface
can initiate a cascade of events including the activation of
NADPH oxidase and of various pro-inflammatory mediators
such as VCAM-1, thus aggravating the generated oxidative
stress.
RAGEs were initially identified as specific receptors for
AGEs [116]. Nowadays, it is known that they are multi-
binding receptors, belonging to the super-family of immu-
noglobulins, which are able to interact with distinct
molecules implicated in homeostasis, in inflammatory
reactions, and in the development of certain pathologies
such as diabetes mellitus and Alzheimer’s disease [90]. In
diabetic patients, the increased expression of these receptors
has been attributed to a wide range of tissues and cells,
namely the epithelium, the endothelium, smooth vascular
muscle, mononuclear inflammatory cells, the glomerulus
and the skin [65]; additionally, AGEs have also been
identified in organic fluids of DM2 patients, such as serum
and saliva, as well as in skin, confirming an increase in the
progression of related complications [53].
The class of S100A12 proteins consists of pro-inflammatory
cytokines, mainly expressed by granulocytes, and are
involved in the transduction of intercellular signalling events
of Ca2+ [16], with a possible influence in the inflammatory
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process and in autoimmune diseases [76]. The AGEs and
the S100/Calgranulins are those which have been most
studied as agents of proinflammatory signalling [43, 105]
and which appear to trigger intercellular signalling mech-
anisms that could participate in some of the pathologies
associated with diabetes, such as nephropathy [91], reti-
nopathy [14], cardiovascular diseases [68] and loss of bone
mass [42].
The treatment of diabetic mice submitted to accelerated
arteriosclerosis, through the soluble extra-cellular domain
of the RAGE, completely suppressed diabetic atherosclero-
sis in a glycaemia- and lipid-independent manner [97].
These findings demonstrate that the interaction of the AGEs
with their receptors appears to be involved in the
development of accelerated arteriosclerosis in diabetes,
reinforcing the attention to be paid to these receptors as
possible targets with a therapeutic potential for macro- and
micro-vascular diseases in diabetes [115].
Diabetic retinopathy Diabetic complications in the retina
result from functional and morphological alterations of the
local capillaries, such as an increase in the permeability to
albumin and other macro-molecules, vascular dysfunction,
loss of pericytes, and thickening of the basal membrane.
Capillary occlusion is responsible for the local occurrence
of impaired blood perfusion (ischaemic retinopathy), which
motivates the secretion of vascular endothelial growth
factors with the neoformation of veins (proliferative
retinopathy) [109].
The role of the AGEs has also been analysed in diabetic
mice treated with an AGE inhibitor: Treatment with
aminoguanidine, compared to control animals, resulted in
a reduction of 75% in the thickness of the basal membrane
of the retinal capillaries [17], in a reduced loss of pericytes
[36], in the absence of a development of micro-aneurisms
[59] and in the proliferation of endothelial cells [83], in
addition to an absence of the accumulation of AGEs in the
arterioles [59]. The preventive effect observed in the animal
model with an AGE inhibitor, namely through amino-
guanidine, lends support to the role of AGEs in the
development of the pathophysiological framework for
diabetic retinopathy. An increase in vascular permeability
was associated in vitro with endothelial endocytosis. An
increase in endocytosis in vascular endothelial cells of the
retina has been observed with elevated concentrations of
glucose, and this could be reduced by aminoguanidine,
suggesting also that this alteration is mediated by the AGEs
[125].
Diabetic nephropathy Diabetic nephropathy is predomi-
nantly characterised by the abnormal depositing of proteins
in the glomerular mesangial space, such as type IV and type
V collagen, laminin and fibronectin, leading to its expan-
sion and, consequently, to the progressive occlusion of
capillaries with consequent renal dysfunction. Two pre-
dominant mechanisms should be considered in this process,
namely the enlargement of cells and the expansion of the
mesangial matrix; the latter is apparently a determinant
factor in the progression of renal disease associated with
diabetes [123]. Various authors have described a direct
relationship between levels of hyperglycaemia and the
lesions observed in diabetic nephropathy, principally in
the expansion of the mesangial matrix (e.g., [12, 13]). On
the other hand, a close relationship has also been shown
between serum and tissue levels of AGEs and the
occurrence of functional renal alterations [130], with an
increased amount of these products in the mesangium and
in the glomerular basal membranes of diabetic patients.
CML seems to be the most abundant AGE type in the
mesangium (96%), in the glomerular basal membranes
(42%), in the tubular basal membranes (85%) and in the
vein walls (96%). Pentosidine appears to be preferentially
localised in the interstitial collagen (90%) and, in compar-
ison to CML, presents a less consistent concentration in the
mesangium (77%), in the glomerular basal membranes
(4%) and in the tubular basal membranes (31%) [131]. The
presence of these compounds in renal structures may
contribute to the tissue lesions described in diabetes, thus
altering the architecture of the extra-cellular matrix through
glycation reactions with the formation of protein cross links
[28, 123]. Another mechanism that appears to participate in
the pathogenesis of nephropathy is also mediated by the
AGEs through their interaction with the RAGEs [148], as
well as by the deregulation of these receptors, particularly
at the podocytes [57]. Indeed, a direct relationship between
serum levels of circulating RAGEs and AGEs and the
severity of the nephropathy in DM2 patients has been
established [130]. In another longitudinal study performed
with type 1 diabetic patients followed up over 2.5 years, the
predictive value of AGE serum levels for the development
of morphological alterations in the kidneys was highlighted
[18].
Diabetic neuropathy Peripheral and autonomic neuropa-
thies are the most frequent manifestations of diabetic
neuropathy, both as independent predictors of ulcerations
and amputations of the lower limb, and they are related to
the mortality associated with diabetes [49]. Diabetic
neuropathy increases with age and with the evolution of
the disease and is present in more than 50% of DM2
patients older than 60 years of age [149]. An increased skin
auto-fluorescence has been described in diabetes, which is
directly correlated with the severity of peripheral and
autonomic nervous dysfunction, with the patient’s age,
with the time period of the disease, with average HbA1c
levels over the preceding years and with the occurrence of
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ulcerations of the lower limbs [84]. These observations
suggest that the determination of AGEs in the skin by
autofluorescence may constitute an important tool for the
early diagnosis of diabetic neuropathy. From the several
chronic complications of diabetes, neuropathic physiopa-
thology has been the most difficult to be associated with
AGEs.
Various studies suggest that the irreversible glycation of
the cytoskeletal proteins in axons of peripheral nerves is
responsible for the formation of cross-links and for the
occurrence of functional alterations in neurons, especially
axonal degeneration [86, 112, 113]. Other authors also
propose the contribution of peripheral arterial occlusion to
this process, and this link is supported by the similar pattern
distribution between the areas showing ischaemia and
neuropathic alterations [26, 146]. Irreversible links between
AGEs and the myelin proteins have also been described,
which appear to contribute to the process of segmental
demyelination observed in the peripheral nerves of diabetic
patients and of aged subjects [141]. The phagocytosis of
glycated myelin by macrophages was described in vitro,
leading to the assumption that these cells are also able to
secrete proteases to the extra-cellular medium, which may
further contribute to the nerve demyelination observed in
diabetic neuropathy [142]. This demyelination and axonal
degeneration should explain the diminution in the speed of
sensible and motor nervous conduction in the peripheral
nerves associated with diabetes and aging [70]. In fact,
diabetic patients followed up over 8 years showed a
reduction of 1.3 m/s in the speed of nervous impulse
conduction in the peroneal, posterior tibial and sural nerves
when the HbA1 levels increased by 1% [9]. Additionally,
the interaction between AGEs and RAGEs seems to
activate the transcription factor NF-κB in the micro-
vascular environment [21], which plays a central role in
sensorial neural dysfunction and, therefore, might contribute
to the physiopathology of diabetic neuropathy [20].
AGEs and regular physical activity
Several publications report the beneficial effects of lifestyle
intervention programmes on DM2 prevention [77, 133], as
well as on the improvement of glycaemic control, with a
consequent delay of chronic complications in diabetic
patients [23, 75]. In these patients, the simple diminution
of 1% in HbA1c has reduced the overall risk of death by
21%, of fatal and non-fatal myocardial infarction events by
14%, of fatal and non-fatal cardiac arrests by 12%, of
micro-vascular complications by 37%, of required cataract
surgeries by 19%, of the number of amputations by 43%
and of cardiac insufficiency incidents by 16% [128].
The practice of regular physical activity has displayed a
positive relationship with the improvement of glycaemic
control in patients with DM2 through the diminution of
fasting glycaemia [41, 72, 132] and HbA1c [22, 31, 41, 45,
72, 82, 132, 139]. However, some authors were unable to
observe this association [117], which could be explained by
the different methodology used (questionnaires) to determine
physical activity levels.
In spite of the number of works analysing the control of
glycaemia through regular physical activity [23, 24, 29, 31,
32, 45–47, 60, 72, 73, 78, 79, 82, 119, 132, 152], very few
have focused on the effects of physical activity on the
formation of AGEs in diabetic patients and/or during aging
[96, 98]. It can nevertheless be assumed that regular
physical activity, as an integrated part of an active lifestyle,
may influence the accumulation of AGEs in the organism
because the amount of these compounds is conditioned by
glycaemia levels [58]. Therefore, the improvements of
glycaemic control in DM2 due to physical exercise, usually
linked with the reduction of the peripheral resistance to
insulin [37, 72, 132], could attenuate the formation and
accumulation of AGEs in the tissue.
However, because of its irreversible character, a signifi-
cant diminution of AGEs affecting tissue proteins of low
turnover, such as collagen [11, 122], elastin [69, 122] and
myelin [66, 112], cannot be predicted. Regarding oxidative
stress, it is assumed that regular physical activity contributes
to an augmentation of the antioxidant capacity, facilitating a
more efficient combat against the formation of ROS [39, 71,
72, 104]. However, when a subject is unaccustomed to
exercise or when it is practised too intensively, it can induce
considerable oxidative stress and damage to the exercised
muscles, affecting capillaries, muscle fibres and connective
tissue [44].
In a recent study, a reduction in the antioxidant enzyme
capacity was observed in red blood cells of diabetic mice,
showing a negative correlation with hyperglycaemia, and
was attenuated by the administration of aminoguanidine
[126]. Some authors argue that AGE formation may
contribute to the antioxidant diminution observed in uncom-
pensated diabetes, where the loss of glucose homeostasis,
with the consequent glycation of antioxidant enzymes such
as catalase, glutathione peroxidase, glutathione reductase and
reduced glutathione, may attenuate their activity [1, 114].
The hyper-production of free radicals during unbalanced
diabetes also appears to interfere at the level of endothelial
dysfunction by the reduction of nitric oxide production,
leading to impairment in vasodilatation by smooth muscle
cells [144]. On the other hand, the AGEs can also increase
the susceptibility to LDL oxidation, which will diminish the
production of endothelial nitric oxide [28]. Therefore, the
association between oxidative stress and AGEs may explain,
at least in part, the close relationship between hyper-
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glycaemia, endothelial dysfunction, and tissue damage,
namely through the observation of correlations between
microvascular lesions and the accumulation of AGEs in
diabetic patients with retinopathy and nephropathy [145]. It
has also been observed that the formation of AGEs can be
retarded or attenuated, but not completely abolished, through
an efficient glycaemic control [134]. In this sense, the option
of the regular practice of physical activity could be one
interesting approach to controlling glycaemia through the
reduction of peripheral resistance to insulin, attenuating the
formation of AGEs, as well as associated oxidative stress
[24, 45]. Moreover, the enhancement of the antioxidant
enzymatic capacity [63], the improvement of vasodilatation
capacity of blood vessels [38] and the favourable modifica-
tions of lipoprotein blood profile [6, 32] and the increment of
LDL oxidation resistance [150] have also been described as
favourable adaptations of diabetic patients taking part in
physical exercise programmes. All these advantages may
also be complemented by the improvement in the profile of
inflammatory markers induced by physical exercise in
diabetic patients, namely a diminution of the C-reactive
protein [54, 67, 103], IL-1 [54], IL-6 [40, 54, 67], IL-8 [93],
IL-18 [67], tumour necrosis factor-α [67], interferon γ [54]
and ICAM-1 [151] and an increase in IL-10 [54].
There appears to be a scarcity of studies which have
looked at the effects of regular physical exercise on AGE
formation, analysing not only the regularity and intensity of
this exercise but also the aspects related to its interaction
with exogenous sources of those compounds. However, the
existing body of literature on this topic allows speculation
that the implementation of structured and controlled
programmes designed to increase the levels of regular
physical activity among DM2 patients, in conjunction with
a hypo-calorific diet poor in AGEs, would be fundamental
for diminishing the risk of early triggering of chronic
diabetic complications and for increasing their physical,
psychological and social well being. It is, however,
necessary to consider the real impact of the implementation
of physical exercise programmes, especially among the
population of advanced age with inherent physical limi-
tations where these programmes may exaggerate the acute
stress normally induced by physical exercise. Indeed, some
evidence [1] has reinforced the concept of the lower
capacity of diabetic patients to tolerate elevated levels of
physical activity, partially due to their greater vulnerability
to the oxidative stress and damage.
References
1. Abou-Seif MA, Youssef AA (2004) Evaluation of some
biochemical changes in diabetic patients. Clin Chim Acta
346:161–170
2. Ahmed N (2005) Advanced glycation endproducts—role in
pathology of diabetic complications. Diabetes Res Clin Pract
67:3–21
3. Ahmed N, Ahmed U, Thornalley PJ, Hager K, Fleischer G, Munch
G (2005) Protein glycation, oxidation and nitration adduct residues
and free adducts of cerebrospinal fluid in Alzheimer’s disease and
link to cognitive impairment. J Neurochem 92:255–263
4. Ahmed N, Babaei-Jadidi R, Howell SK, Beisswenger PJ,
Thornalley PJ (2005) Degradation products of proteins damaged
by glycation, oxidation and nitration in clinical type 1 diabetes.
Diabetologia 48:1590–1603
5. Ahmed N, Thornalley PJ (2003) Quantitative screening of
protein biomarkers of early glycation, advanced glycation,
oxidation and nitrosation in cellular and extracellular proteins
by tandem mass spectrometry multiple reaction monitoring.
Biochem Soc Trans 31:1417–1422
6. Ainslie PN, Reilly T, Maclaren DP, Campbell IT (2005) Changes
in plasma lipids and lipoproteins following 10-days of prolonged
walking: influence of age and relationship to physical activity
level. Ergonomics 48:1352–1364
7. Al-Abed Y, Bucala R (2000) Structure of a synthetic glucose
derived advanced glycation end product that is immunologically
cross-reactive with its naturally occurring counterparts. Bioconjug
Chem 11:39–45
8. Al-Abed Y, Mitsuhashi T, Li H, Lawson JA, FitzGerald GA,
Founds H, Donnelly T, Cerami A, Ulrich P, Bucala R (1999)
Inhibition of advanced glycation endproduct formation by
acetaldehyde: role in the cardioprotective effect of ethanol. Proc
Natl Acad Sci U S A 96:2385–2390
9. Amthor KF, Dahl-Jorgensen K, Berg TJ, Heier MS, Sandvik L,
Aagenaes O, Hanssen KF (1994) The effect of 8 years of strict
glycaemic control on peripheral nerve function in IDDM
patients: the Oslo Study. Diabetologia 37:579–584
10. Armoni M, Harel C, Burvin R, Karnieli E (1995) Modulation of
the activity of glucose transporters (GLUT) in the aged/obese rat
adipocyte: suppressed function, but enhanced intrinsic activity of
GLUT. Endocrinology 136:3292–3298
11. Avery NC, Bailey AJ (2005) Enzymic and non-enzymic cross-
linking mechanisms in relation to turnover of collagen: relevance
to aging and exercise. Scand J Med Sci Sports 15:231–240
12. Bangstad HJ, Osterby R, Dahl-Jorgensen K, Berg KJ, Hartmann
A, Hanssen KF (1994) Improvement of blood glucose control in
IDDM patients retards the progression of morphological changes
in early diabetic nephropathy. Diabetologia 37:483–490
13. Barbosa J, Steffes MW, Sutherland DE, Connett JE, Rao KV,
Mauer SM (1994) Effect of glycemic control on early diabetic
renal lesions. A 5-year randomized controlled clinical trial of
insulin-dependent diabetic kidney transplant recipients. JAMA
272:600–606
14. Barile GR, Pachydaki SI, Tari SR, Lee SE, Donmoyer CM, Ma
W, Rong LL, Buciarelli LG, Wendt T, Horig H, Hudson BI, Qu
W, Weinberg AD, Yan SF, Schmidt AM (2005) The RAGE axis
in early diabetic retinopathy. Invest Ophthalmol Vis Sci
46:2916–2924
15. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu
C, Kislinger T, Stern DM, Schmidt AM, De Caterina R (2002)
Advanced glycation end products activate endothelium through
signal-transduction receptor RAGE: a mechanism for amplification
of inflammatory responses. Circulation 105:816–822
16. Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E,
Casolaro A, Natali A, Ferrannini E, Gastaldelli A (2006)
Circulating soluble receptor for advanced glycation end-products
(sRAGE) is inversely associated with glycemic control and
S100A12 protein. J Clin Endocrinol Metab 91:4628–4634
17. Beisswenger PJ, Moore LL, Brinck-Johnsen T, Curphey TJ
(1993) Increased collagen-linked pentosidine levels and
24 Eur Rev Aging Phys Act (2008) 5:17–29
advanced glycosylation end products in early diabetic nephropathy.
J Clin Invest 92:212–217
18. Berg TJ, Bangstad HJ, Torjesen PA, Osterby R, Bucala R,
Hanssen KF (1997) Advanced glycation end products in serum
predict changes in the kidney morphology of patients with
insulin-dependent diabetes mellitus. Metabolism 46:661–665
19. Bidasee KR, Nallani K, Yu Y, Cocklin RR, Zhang Y, Wang M,
Dincer UD, Besch HR (2003) Chronic diabetes increases
advanced glycation end products on cardiac ryanodine receptors/
calcium-release channels. Diabetes 52:1825–1836
20. Bierhaus A, Haslbeck KM, Humpert PM, Liliensiek B, Dehmer T,
Morcos M, Sayed AA, Andrassy M, Schiekofer S, Schneider JG,
Schulz JB, Heuss D, Neundorfer B, Dierl S, Huber J, Tritschler H,
Schmidt AM, Schwaninger M, Haering HU, Schleicher E, Kasper
M, Stern DM, Arnold B, Nawroth PP (2004) Loss of pain
perception in diabetes is dependent on a receptor of the
immunoglobulin superfamily. J Clin Invest 114:1741–1751
21. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert
PM, Chen J, Hong M, Luther T, Henle T, Kloting I, Morcos M,
Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry
G, Schmidt AM, Stern DM, Haring HU, Schleicher E, Nawroth
PP (2001) Diabetes-associated sustained activation of the
transcription factor nuclear factor-kappaB. Diabetes 50:2792–2808
22. Bjorgaas M, Vik JT, Saeterhaug A, Langlo L, Sakshaug T,
Mohus RM, Grill V (2005) Relationship between pedometer-
registered activity, aerobic capacity and self-reported activity and
fitness in patients with type 2 diabetes. Diabetes Obes Metab
7:737–744
23. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ (2001)
Effects of exercise on glycemic control and body mass in type 2
diabetes mellitus: a meta-analysis of controlled clinical trials.
JAMA 286:1218–1227
24. Brooks N, Layne JE, Gordon PL, Roubenoff R, Nelson ME,
Castaneda-Sceppa C (2006) Strength training improves muscle
quality and insulin sensitivity in Hispanic older adults with type
2 diabetes. Int J Med Sci 4:19–27
25. Brownlee M (1995) Advanced protein glycosylation in diabetes
and aging. Annu Rev Med 46:223–234
26. Brownlee M, Vlassara H, Cerami A (1986) Trapped immuno-
globulins on peripheral nerve myelin from patients with diabetes
mellitus. Diabetes 35:999–1003
27. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A (1986)
Aminoguanidine prevents diabetes-induced arterial wall protein
cross-linking. Science 232:1629–1632
28. Bucala R, Vlassara H (1995) Advanced glycosylation end
products in diabetic renal and vascular disease. Am J Kidney
Dis 26:875–888
29. Cardoso SS, Feuers RJ, Tsai TH, Hunter JD, Scheving LE
(1990) Chronobiology of exercise: the influence of scheduling
upon glycemic responses of control and of subjects with diabetes
mellitus. Prog Clin Biol Res 341B:345–353
30. Carvalho E, Rondinone C, Smith U (2000) Insulin resistance in
fat cells from obese Zucker rats—evidence for an impaired
activation and translocation of protein kinase B and glucose
transporter 4. Mol Cell Biochem 206:7–16
31. Castaneda C, Layne JE, Munoz-Orians L, Gordon PL, Walsmith
J, Foldvari M, Roubenoff R, Tucker KL, Nelson ME (2002) A
randomized controlled trial of resistance exercise training to
improve glycemic control in older adults with type 2 diabetes.
Diabetes Care 25:2335–2341
32. Cauza E, Hanusch-Enserer U, Strasser B, Kostner K, Dunky A,
Haber P (2006) The metabolic effects of long term exercise in
Type 2 Diabetes patients. Wien Med Wochenschr 156:515–519
33. Cerami A, Vlassara H, Brownlee M (1988) Role of advanced
glycosylation products in complications of diabetes. Diabetes
Care 11(Suppl 1):73–79
34. Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D,
Vanpatten S, Lee A, Al-Abed Y, Vlassara H, Bucala R, Cerami A
(1997) Tobacco smoke is a source of toxic reactive glycation
products. Proc Natl Acad Sci U S A 94:13915–13920
35. Ceriello A (1999) Hyperglycaemia: the bridge between non-
enzymatic glycation and oxidative stress in the pathogenesis of
diabetic complications. Diabetes Nutr Metab 12:42–46
36. Chibber R, Molinatti PA, Wong JS, Mirlees D, Kohner EM
(1994) The effect of aminoguanidine and tolrestat on glucose
toxicity in bovine retinal capillary pericytes. Diabetes 43:
758–763
37. Cuff DJ, Meneilly GS, Martin A, Ignaszewski A, Tildesley HD,
Frohlich JJ (2003) Effective exercise modality to reduce insulin
resistance in women with type 2 diabetes. Diabetes Care
26:2977–2982
38. De Filippis E, Cusi K, Ocampo G, Berria R, Buck S, Consoli A,
Mandarino LJ (2006) Exercise-induced improvement in vasodilatory
function accompanies increased insulin sensitivity in obesity and
type 2 diabetes mellitus. J Clin Endocrinol Metab 91:4903–4910
39. Dekany M, Nemeskeri V, Gyore I, Harbula I, Malomsoki J,
Pucsok J (2006) Antioxidant status of interval-trained athletes in
various sports. Int J Sports Med 27:112–116
40. Dekker MJ, Lee S, Hudson R, Kilpatrick K, Graham TE, Ross R,
Robinson LE (2007) An exercise intervention without weight loss
decreases circulating interleukin-6 in lean and obese men with and
without type 2 diabetes mellitus. Metabolism 56:332–338
41. Di Loreto C, Fanelli C, Lucidi P, Murdolo G, De Cicco A,
Parlanti N, Ranchelli A, Fatone C, Taglioni C, Santeusanio F, De
Feo P (2005) Make your diabetic patients walk: long-term
impact of different amounts of physical activity on type 2
diabetes. Diabetes Care 28:1295–1302
42. Ding KH, Wang ZZ, Hamrick MW, Deng ZB, Zhou L, Kang B,
Yan SL, She JX, Stern DM, Isales CM, Mi QS (2006)
Disordered osteoclast formation in RAGE-deficient mouse
establishes an essential role for RAGE in diabetes related bone
loss. Biochem Biophys Res Commun 340:1091–1097
43. Ding Y, Kantarci A, Hasturk H, Trackman PC, Malabanan A,
Van Dyke TE (2007) Activation of RAGE induces elevated O2-
generation by mononuclear phagocytes in diabetes. J Leukoc
Biol 81:520–527
44. Duarte JA, Appell HJ, Carvalho F, Bastos ML, Soares JM (1993)
Endothelium-derived oxidative stress may contribute to exercise-
induced muscle damage. Int J Sports Med 14:440–443
45. Dunstan DW, Daly RM, Owen N, Jolley D, De Courten M,
Shaw J, Zimmet P (2002) High-intensity resistance training
improves glycemic control in older patients with type 2 diabetes.
Diabetes Care 25:1729–1736
46. Dunstan DW, Mori TA, Puddey IB, Beilin LJ, Burke V, Morton
AR, Stanton KG (1997) The independent and combined effects
of aerobic exercise and dietary fish intake on serum lipids and
glycemic control in NIDDM. A randomized controlled study.
Diabetes Care 20:913–921
47. Dunstan DW, Vulikh E, Owen N, Jolley D, Shaw J, Zimmet P
(2006) Community center-based resistance training for the
maintenance of glycemic control in adults with type 2 diabetes.
Diabetes Care 29:2586–2591
48. Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance
DR, Baynes JW (1993) Accumulation of Maillard reaction
products in skin collagen in diabetes and aging. J Clin Invest
91:2463–2469
49. Ewing DJ, Campbell IW, Clarke BF (1976) Mortality in diabetic
autonomic neuropathy. Lancet 1:601–603
50. Flecha LG, Castello PR, Gagliardino JJ, Rossi JP (2000) La
glucosilación no enzimática de proteínas. Mecanismo y papel de
la reacción en la diabetes y el envejecimiento. Cienc Día Int 3:
1–17
Eur Rev Aging Phys Act (2008) 5:17–29 25
51. Fodor JG, Adamo KB (2001) Prevention of type 2 diabetes
mellitus by changes in lifestyle. N Engl J Med 345:696 author
reply 696–697
52. Frye EB, Degenhardt TP, Thorpe SR, Baynes JW (1998) Role of
the Maillard reaction in aging of tissue proteins. Advanced
glycation end product-dependent increase in imidazolium cross-
links in human lens proteins. J Biol Chem 273:18714–18719
53. Garay-Sevilla ME, Regalado JC, Malacara JM, Nava LE,
Wrobel-Zasada K, Castro-Rivas A, Wrobel K (2005) Advanced
glycosylation end products in skin, serum, saliva and urine and
its association with complications of patients with type 2
diabetes mellitus. J Endocrinol Invest 28:223–230
54. Goldhammera E, Tanchilevitcha A, Maorb I, Beniaminia Y,
Rosenscheina U, Sagivc M (2005) Exercise training modulates
cytokines activity in coronary heart disease patients. Int J Cardiol
100:93–99
55. Greenwald SE (2007) Ageing of the conduit arteries. J Pathol
211:157–172
56. The Diabetes Control and Complications Trial Research Group
(1993) The effect of intensive treatment of diabetes on the
development and progression of long-term complications in
insulin-dependent diabetes mellitus. The Diabetes Control and
Complications Trial Research Group. N Engl J Med 329:977–986
57. Gu L, Hagiwara S, Fan Q, Tanimoto M, Kobata M, Yamashita
M, Nishitani T, Gohda T, Ni Z, Qian J, Horikoshi S, Tomino Y
(2006) Role of receptor for advanced glycation end-products and
signalling events in advanced glycation end-product-induced
monocyte chemoattractant protein-1 expression in differentiated
mouse podocytes. Nephrol Dial Transplant 21:299–313
58. Hammes H-P, Wellensiek B, Kloting I, Sickel E, Bretzel R,
Brownlee M (1998) The relationship of glycaemic level to
advanced glycation end-product (AGE) accumulation and retinal
pathology in the spontaneous diabetic hamster. Diabetologia
41:165–170
59. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M
(1991) Aminoguanidine treatment inhibits the development of
experimental diabetic retinopathy. Proc Natl Acad Sci U S A
88:11555–11558
60. Heath GW, Wilson RH, Smith J, Leonard BE (1991) Community-
based exercise and weight control: diabetes risk reduction and
glycemic control in Zuni Indians. Am J Clin Nutr 53:1642S–
1646S
61. Ikeda K, Higashi T, Sano H, Jinnouchi Y, Yoshida M, Araki T,
Ueda S, Horiuchi S (1996) N (epsilon)-(carboxymethyl)lysine
protein adduct is a major immunological epitope in proteins
modified with advanced glycation end products of the Maillard
reaction. Biochemistry 35:8075–8083
62. Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF
(1999) Serum levels of advanced glycation end products are
increased in patients with type 2 diabetes and coronary heart
disease. Diabetes Care 22:1543–1548
63. Kim JD, McCarter RJ, Yu BP (1996) Influence of age, exercise,
and dietary restriction on oxidative stress in rats. Aging (Milano)
8:123–129
64. Kim JW, No JK, Ikeno Y, Yu BP, Choi JS, Yokozawa T, Chung
HY (2002) Age-related changes in redox status of rat serum.
Arch Gerontol Geriatr 34:9–17
65. Kim W, Hudson BI, Moser B, Guo J, Rong LL, Lu YAN, Qu
WU, Lalla E, Lerner S, Chen Y, Yan SSD, D’Agati V, Naka Y,
Ramasamy R, Herold K, Yan SF, Schmidt AM (2005) Receptor
for advanced glycation end products and its ligands: a journey
from the complications of diabetes to its pathogenesis. Ann N Y
Acad Sci 1043:553–561
66. Kirschner DA, Eichberg J (1994) Restricted hypotonic swelling
of peripheral nerve myelin in streptozocin-induced diabetic rats.
J Neurosci Res 38:142–148
67. Kohut ML, McCann DA, Russell DW, Konopka DN, Cunnick
JE, Franke WD, Castillo MC, Reighard AE, Vanderah E (2006)
Aerobic exercise, but not flexibility/resistance exercise, reduces
serum IL-18, CRP, and IL-6 independent of beta-blockers, BMI,
and psychosocial factors in older adults. Brain Behav Immun
20:201–209
68. Koka V, Wang W, Huang XR, Kim-Mitsuyama S, Truong LD,
Lan HY (2006) Advanced glycation end products activate a
chymase-dependent angiotensin II-generating pathway in diabetic
complications. Circulation 113:1353–1360
69. Konova E, Baydanoff S, Atanasova M, Velkova A (2004) Age-
related changes in the glycation of human aortic elastin. Exp
Gerontol 39:249–254
70. Koura NH (2003) A comparison of sciatic nerve neuropathy in
diabetic and aged rats. Folia Biol (Krakow) 51:213–218
71. Laufs U, Wassmann S, Czech T, Munzel T, Eisenhauer M, Bohm
M, Nickenig G (2005) Physical inactivity increases oxidative
stress, endothelial dysfunction, and atherosclerosis. Arterioscler
Thromb Vasc Biol 25:809–814
72. Lazarevic G, Antic S, Cvetkovic T, Vlahovic P, Tasic I,
Stefanovic V (2006) A physical activity programme and its
effects on insulin resistance and oxidative defense in obese male
patients with type 2 diabetes mellitus. Diabetes Metab 32:583–
590
73. Lee HJ, Park KY, Park HS, Kim IJ (2005) The effects of problem
solving nursing counseling and intensified walking exercise on
diabetic self-care, coping strategies, and glycemic control among
clients with DM Type II. Taehan Kanho Hakhoe Chi 35:1314–
1324
74. Li SY, Du M, Dolence EK, Fang CX, Mayer GE, Ceylan-Isik
AF, LaCour KH, Yang X, Wilbert CJ, Sreejayan N, Ren J (2005)
Aging induces cardiac diastolic dysfunction, oxidative stress,
accumulation of advanced glycation endproducts and protein
modification. Aging Cell 4:57–64
75. Lim J, Kang H, Stewart K (2004) Type 2 diabetes in Singapore:
the role of exercise training for its prevention and management.
Singapore Med J 45:62–68
76. Lindholm E, Bakhtadze E, Sjogren M, Cilio CM, Agardh E,
Groop L, Agardh CD (2006) The −374 T/A polymorphism in the
gene encoding RAGE is associated with diabetic nephropathy
and retinopathy in type 1 diabetic patients. Diabetologia
49:2745–2755
77. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG,
Hemio K, Hamalainen H, Harkonen P, Keinanen-Kiukaanniemi S,
Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle
TT, Uusitupa M, Tuomilehto J (2006) Sustained reduction in the
incidence of type 2 diabetes by lifestyle intervention: follow-up of
the Finnish Diabetes Prevention Study. Lancet 368:1673–1679
78. Loimaala A, Huikuri HV, Koobi T, Rinne M, Nenonen A, Vuori
I (2003) Exercise training improves baroreflex sensitivity in type
2 diabetes. Diabetes 52:1837–1842
79. MacDonald AL, Philp A, Harrison M, Bone AJ, Watt PW (2006)
Monitoring exercise-induced changes in glycemic control in type
2 diabetes. Med Sci Sports Exerc 38:201–207
80. Machiels D, Istasse L (2002) La réaction deMaillard: importance et
applications en chimie des aliments. Ann Méd Vét 146:347–352
81. Maillard L (1912) Formation dhumus et de combustibles
minéraux sans intervention de l’oxygéne atmosphérique, des
micro-organismes, des hautes températures ou fortes pressions. C
R Acad Sci (Paris) 1912:1554–1556
82. Maiorana A, O’Driscoll G, Goodman C, Taylor R, Green D
(2002) Combined aerobic and resistance exercise improves
glycemic control and fitness in type 2 diabetes. Diabetes Res
Clin Pract 56:115–123
83. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thorpe SR,
Baynes JW, Lyons TJ (1993) Maillard reaction products and
26 Eur Rev Aging Phys Act (2008) 5:17–29
their relation to complications in insulin-dependent diabetes
mellitus. J Clin Invest 91:2470–2478
84. Meerwaldt R, Links TP, Graaff R, Hoogenberg K, Lefrandt JD,
Baynes JW,Gans RO, Smit AJ (2005) Increased accumulation of skin
advanced glycation end-products precedes and correlates with clinical
manifestation of diabetic neuropathy. Diabetologia 48:1637–1644
85. Miele C, Riboulet A, Maitan MA, Oriente F, Romano C,
Formisano P, Giudicelli J, Beguinot F, Van Obberghen E
(2003) Human glycated albumin affects glucose metabolism in
L6 skeletal muscle cells by impairing insulin-induced insulin
receptor substrate (IRS) signaling through a protein kinase C
alpha-mediated mechanism. J Biol Chem 278:47376–47387
86. Misur I, Zarkovic K, Barada A, Batelja L, Milicevic Z, Turk Z
(2004) Advanced glycation endproducts in peripheral nerve in
type 2 diabetes with neuropathy. Acta Diabetol 41:158–166
87. Monnier VM, Sell DR, Nagaraj RH, Miyata S, Grandhee S, Odetti
P, Ibrahim SA (1992) Maillard reaction-mediated molecular
damage to extracellular matrix and other tissue proteins in
diabetes, aging, and uremia. Diabetes 41(Suppl 2):36–41
88. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P,
Kohn RR (1986) Relation between complications of type I
diabetes mellitus and collagen-linked fluorescence. N Engl J
Med 314:403–408
89. Moustafa SA, Webster JE, Mattar FE (1995) Effects of aging and
antioxidants on glucose transport in rat adipocytes. Gerontology
41:301–307
90. Mruthinti S, Schade RF, Harrell DU, Gulati NK, Swamy-
Mruthinti S, Lee GP, Buccafusco JJ (2006) Autoimmunity in
Alzheimer’s disease as evidenced by plasma immunoreactivity
against RAGE and Abeta42: complication of diabetes. Curr
Alzheimer Res 3:229–235
91. Myint KM, Yamamoto Y, Doi T, Kato I, Harashima A, Yonekura
H, Watanabe T, Shinohara H, Takeuchi M, Tsuneyama K,
Hashimoto N, Asano M, Takasawa S, Okamoto H, Yamamoto
H (2006) RAGE control of diabetic nephropathy in a mouse
model: effects of RAGE gene disruption and administration of
low-molecular weight heparin. Diabetes 55:2510–2522
92. Nakamura Y, Horii Y, Nishino T, Shiiki H, Sakaguchi Y,
Kagoshima T, Dohi K, Makita Z, Vlassara H, Bucala R (1993)
Immunohistochemical localization of advanced glycosylation
end products in coronary atheroma and cardiac tissue in diabetes
mellitus. Am J Pathol 143:1649–1656
93. Niessner A, Richter B, Penka M, Steiner S, Strasser B, Ziegler S,
Heeb-Elze E, Zorn G, Leitner-Heinschink A, Niessner C, Wojta
J, Huber K (2006) Endurance training reduces circulating
inflammatory markers in persons at risk of coronary events:
impact on plaque stabilization? Atherosclerosis 186:160–165
94. Obayashi H, Nakano K, Shigeta H, Yamaguchi M, Yoshimori K,
Fukui M, Fujii M, Kitagawa Y, Nakamura N, Nakamura K,
Nakazawa Y, Ienaga K, Ohta M, Nishimura M, Fukui I, Kondo
M (1996) Formation of crossline as a fluorescent advanced
glycation end product in vitro and in vivo. Biochem Biophys Res
Commun 226:37–41
95. Omsland TK, Bangstad HJ, Berg TJ, Kolset SO (2006)
Advanced glycation end products and hyperglycaemia. Tidsskr
Nor Laegeforen 126:155–158
96. Panteleeva IG, Rogozkin VA (2001) Effect of physical load on
serum protein glycation in rats with induced diabetes. Ross
Fiziol Zh Im I M Sechenova 87:1202–1207
97. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr., Chow WS,
Stern D, Schmidt AM (1998) Suppression of accelerated diabetic
atherosclerosis by the soluble receptor for advanced glycation
endproducts. Nat Med 4:1025–1031
98. Penelope AM (2005) Lack of age-related increase in average
glycemia in a non-Westernized sample of rural Yucatec Maya
females. Am J Phys Anthropol 126:111–121
99. Peppa M, Brem H, Ehrlich P, Zhang J-G, Cai W, Li Z, Croitoru
A, Thung S, Vlassara H (2003) Adverse effects of dietary
glycotoxins on wound healing in genetically diabetic mice.
Diabetes 52:2805–2813
100. Peppa M, He C, Hattori M, McEvoy R, Zheng F, Vlassara H
(2003) Fetal or neonatal low-glycotoxin environment prevents
autoimmune diabetes in NOD mice. Diabetes 52:1441–1448
101. Perry RE, Swamy MS, Abraham EC (1987) Progressive changes
in lens crystallin glycation and high-molecular-weight aggregate
formation leading to cataract development in streptozotocin-
diabetic rats. Exp Eye Res 44:269–282
102. Radak Z, Chung HY, Naito H, Takahashi R, Jung KJ, Kim HJ,
Goto S (2004) Age-associated increase in oxidative stress and
nuclear factor kappaB activation are attenuated in rat liver by
regular exercise. FASEB J 18:749–750
103. Rahimi K, Secknus MA, Adam M, Hayerizadeh BF, Fiedler M,
Thiery J, Schuler G (2005) Correlation of exercise capacity with
high-sensitive C-reactive protein in patients with stable coronary
artery disease. Am Heart J 150:1282–1289
104. Ramel A, Wagner KH, Elmadfa I (2004) Correlations between
plasma noradrenaline concentrations, antioxidants, and neutrophil
counts after submaximal resistance exercise in men. Br J Sports
Med 38:E22
105. Reddy MA, Li SL, Sahar S, Kim YS, Xu ZG, Lanting L,
Natarajan R (2006) Key role of Src kinase in S100B-induced
activation of the receptor for advanced glycation end products in
vascular smooth muscle cells. J Biol Chem 281:13685–13693
106. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW
(1995) N epsilon-(carboxymethyl)lysine is a dominant advanced
glycation end product (AGE) antigen in tissue proteins.
Biochemistry 34:10872–10878
107. Rett K (1999) The relation between insulin resistance and
cardiovascular complications of the insulin resistance syndrome.
Diabetes Obes Metab 1(Suppl 1):S8–16
108. Riboulet-Chavey A, Pierron A, Durand I, Murdaca J, Giudicelli J,
Van Obberghen E (2006) Methylglyoxal impairs the insulin
signaling pathways independently of the formation of intracellular
reactive oxygen species. Diabetes 55:1289–1299
109. Roguin A, Nitecki S, Rubinstein I, Nevo E, Avivi A, Levy NS,
Abassi ZA, Sabo E, Lache O, Frank M, Hoffman A, Levy P
(2003) Vascular endothelial growth factor (VEGF) fails to
improve blood flow and to promote collateralization in a diabetic
mouse ischemic hindlimb model. Cardiovasc Diabetol 2:18
110. Roscic M, Horvat S (2006) Transformations of bioactive
peptides in the presence of sugars—characterization and stability
studies of the adducts generated via the Maillard reaction. Bioorg
Med Chem 14:4933–4943
111. Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L
(2001) The role of oxidative stress in the onset and progression
of diabetes and its complications: a summary of a Congress
Series sponsored by UNESCO-MCBN, the American Diabetes
Association and the German Diabetes Society. Diabetes Metab
Res Rev 17:189–212
112. Ryle C, Donaghy M (1995) Non-enzymatic glycation of
peripheral nerve proteins in human diabetics. J Neurol Sci
129:62–68
113. Ryle C, Leow CK, Donaghy M (1997) Nonenzymatic glycation
of peripheral and central nervous system proteins in experimental
diabetes mellitus. Muscle Nerve 20:577–584
114. Sailaja Devi MM, Suresh Y, Das UN (2000) Preservation of the
antioxidant status in chemically-induced diabetes mellitus by
melatonin. J Pineal Res 29:108–115
115. Schmidt AM, Stern D (2000) Atherosclerosis and diabetes: the
RAGE connection. Curr Atheroscler Rep 2:430–436
116. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J,
Esposito C, Hegarty H, Hurley W, Clauss M et al (1992)
Eur Rev Aging Phys Act (2008) 5:17–29 27
Isolation and characterization of two binding proteins for
advanced glycosylation end products from bovine lung which
are present on the endothelial cell surface. J Biol Chem
267:14987–14997
117. Selam JL, Casassus P, Bruzzo F, Leroy C, Slama G (1992)
Exercise is not associated with better diabetes control in type 1
and type 2 diabetic subjects. Acta Diabetol 29:11–13
118. Sevilla L, Guma A, Enrique-Tarancon G, Mora S, Munoz P,
Palacin M, Testar X, Zorzano A (1997) Chronic high-fat feeding
and middle-aging reduce in an additive fashion Glut4 expression
in skeletal muscle and adipose tissue. Biochem Biophys Res
Commun 235:89–93
119. Sigal RJ, Kenny GP, Boule NG, Wells GA, Prud’homme D,
Fortier M, Reid RD, Tulloch H, Coyle D, Phillips P, Jennings A,
Jaffey J (2007) Effects of aerobic training, resistance training, or
both on glycemic control in type 2 diabetes: a randomized trial.
Ann Intern Med 147:357–369
120. Sims TJ, Rasmussen LM, Oxlund H, Bailey AJ (1996) The role of
glycation cross-links in diabetic vascular stiffening. Diabetologia
39:946–951
121. Smith MA, Taneda S, Richey PL, Miyata S, Yan S, Stern D,
Sayre LM, Monnier VM, Perry G (1994) Advanced Maillard
reaction end products are associated with Alzheimer disease
pathology. Proc Natl Acad Sci U S A 91:5710–5714
122. Stamatas GN, Estanislao RB, Suero M, Rivera ZS, Li J, Khaiat
A, Kollias N (2006) Facial skin fluorescence as a marker of the
skin’s response to chronic environmental insults and its dependence
on age. Br J Dermatol 154:125–132
123. Steffes MW, Bilous RW, Sutherland DE, Mauer SM (1992) Cell
and matrix components of the glomerular mesangium in type I
diabetes. Diabetes 41:679–684
124. Stirban A, Negrean M, Stratmann B, Gawlowski T, Horstmann T,
Gotting C, Kleesiek K, Mueller-Roesel M, Koschinsky T, Uribarri
J, Vlassara H, Tschoepe D (2006) Benfotiamine prevents macro-
and microvascular endothelial dysfunction and oxidative stress
following a meal rich in advanced glycation end products in
individuals with type 2 diabetes. Diabetes Care 29:2064–2071
125. Stitt AW, Chakravarthy U, Archer DB, Gardiner TA (1995)
Increased endocytosis in retinal vascular endothelial cells grown
in high glucosemedium is modulated by inhibitors of nonenzymatic
glycosylation. Diabetologia 38:1271–1275
126. Stoppa GR, Cesquini M, Roman EA, Ogo SH, Torsoni MA (2006)
Aminoguanidine prevented impairment of blood antioxidant
system in insulin-dependent diabetic rats. Life Sci 78:1352–1361
127. Stopper H, Schinzel R, Sebekova K, Heidland A (2003)
Genotoxicity of advanced glycation end products in mammalian
cells. Cancer Lett 190:151–156
128. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull
CA, Hadden D, Turner RC, Holman RR (2000) Association of
glycaemia with macrovascular and microvascular complications
of type 2 diabetes (UKPDS 35): prospective observational study.
BMJ 321:405–412
129. Suji G, Sivakami S (2004) Glucose, glycation and aging.
Biogerontology 5:365–373
130. Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ
(2006) Association between serum levels of soluble receptor for
advanced glycation end products and circulating advanced
glycation end products in type 2 diabetes. Diabetologia
49:2756–2762
131. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A,
Pischetsrieder M, Stern D, Schmidt AM, D’Agati VD (2000)
Expression of advanced glycation end products and their cellular
receptor RAGE in diabetic nephropathy and nondiabetic renal
disease. J Am Soc Nephrol 11:1656–1666
132. Tokmakidis SP, Zois CE, Volaklis KA, Kotsa K, Touvra AM
(2004) The effects of a combined strength and aerobic exercise
program on glucose control and insulin action in women with
type 2 diabetes. Eur J Appl Physiol 92:437–442
133. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen
H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M,
Louheranta A, Rastas M, Salminen V, Uusitupa M (2001)
Prevention of type 2 diabetes mellitus by changes in lifestyle
among subjects with impaired glucose tolerance. N Engl J Med
344:1343–1350
134. Turk Z, Misur I, Turk N, Benko B (1999) Rat tissue collagen
modified by advanced glycation: correlation with duration of
diabetes and glycemic control. Clin Chem Lab Med 37:813–820
135. UKPDS (1998) Intensive blood-glucose control with sulphonylureas
or insulin compared with conventional treatment and risk of
complications in patients with type 2 diabetes (UKPDS 33). UK
Prospective Diabetes Study (UKPDS) Group. Lancet 352:837–853
136. Unoki H, Bujo H, Yamagishi S, Takeuchi M, Imaizumi T, Saito Y
(2007) Advanced glycation end products attenuate cellular insulin
sensitivity by increasing the generation of intracellular reactive
oxygen species in adipocytes. Diabetes Res Clin Pract 76:236–244
137. Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, He C, Vlassara
H (2003) Restriction of dietary glycotoxins reduces excessive
advanced glycation end products in renal failure patients. J Am
Soc Nephrol 14:728–731
138. Valcourt U, Merle B, Gineyts E, Viguet-Carrin S, Delmas PD,
Garnero P (2006) Non-enzymatic glycations of bone collagen
modify osteoclastic activity and differentiation. J Biol Chem
282:5691–5703
139. van Rooijen AJ, Rheeder P, Eales CJ, Becker PJ (2004) Effect of
exercise versus relaxation on haemoglobin A1C in Black females
with type 2 diabetes mellitus. QJM 97:343–351
140. Vincent AM, Perrone L, Sullivan KA, Backus C, Sastry AM,
Lastoskie C, Feldman EL (2006) RAGE activation injures
primary sensory neurons via oxidative stress. Endocrinology
148:548–558
141. Vlassara H, Brownlee M, Cerami A (1984) Accumulation of
diabetic rat peripheral nerve myelin by macrophages increases
with the presence of advanced glycosylation endproducts. J Exp
Med 160:197–207
142. Vlassara H, Brownlee M, Cerami A (1985) Recognition and uptake
of human diabetic peripheral nerve myelin by macrophages.
Diabetes 34:553–557
143. Vlassara H, Palace MR (2002) Diabetes and advanced glycation
endproducts. J Intern Med 251:87–101
144. Wautier JL, Guillausseau PJ (2001) Advanced glycation end
products, their receptors and diabetic angiopathy. Diabetes
Metab 27:535–542
145. Wautier MP, Boulanger E, Guillausseau PJ, Massin P, Wautier JL
(2004) AGEs, macrophage colony stimulating factor and
vascular adhesion molecule blood levels are increased in patients
with diabetic microangiopathy. Thromb Haemost 91:879–885
146. Weber F, Ziegler A (2002) Axonal neuropathy in chronic
peripheral arterial occlusive disease. Muscle Nerve 26:471–476
147. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global
prevalence of diabetes: estimates for the year 2000 and
projections for 2030. Diabetes Care 27:1047–1053
148. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M,
Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H,
Yamamoto H (2001) Development and prevention of advanced
diabetic nephropathy in RAGE-overexpressing mice. J Clin
Invest 108:261–268
149. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen
PH (1993) A multicentre study of the prevalence of diabetic
28 Eur Rev Aging Phys Act (2008) 5:17–29
peripheral neuropathy in the United Kingdom hospital clinic
population. Diabetologia 36:150–154
150. Yu Y, Thorpe SR, Jenkins AJ, Shaw JN, Sochaski MA, McGee
D, Aston CE, Orchard TJ, Silvers N, Peng YG, McKnight JA,
Baynes JW, Lyons TJ (2006) Advanced glycation end-products
and methionine sulphoxide in skin collagen of patients with type
1 diabetes. Diabetologia 49:2488–2498
151. Ziegler S, Schaller G, Mittermayer F, Pleiner J, Mihaly J,
Niessner A, Richter B, Steiner-Boeker S, Penak M, Strasser B,
Wolzt M (2006) Exercise training improves low-density lipopro-
tein oxidability in untrained subjects with coronary artery
disease. Arch Phys Med Rehabil 87:265–269
152. Zierath JR,Wallberg-HenrikssonH (1992) Exercise training in obese
diabetic patients. Special considerations. Sports Med 14:171–189
Eur Rev Aging Phys Act (2008) 5:17–29 29
